Compare Cheniere Energy (LNG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cheniere Energy vs Organon & Co. Common Stock — how do they compare? Cheniere Energy trades at $280.53 (market cap $59.26B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Cheniere Energy is far larger — about 16.4× Organon & Co. Common Stock's market cap, and Cheniere Energy pays the higher dividend (0.77%). Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 12 Days and Organon & Co. Common Stock for 0 Days on average.
| LNG | OGN | |
|---|---|---|
Market Cap | $59.26B | $3.62B |
Volume | 1,056,751 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $296.91 | $13.81 |
52-Week Low | $188.83 | $5.70 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $84.72B | $11.04B |
Dividend Yield | 0.77% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cheniere Energy (LNG) trades at $286.92, up 1.57% on the day, with a bullish technical signal from moving averages. The stock exhibits strong profitability with a 45.23% ROE and 13.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights the company's long-term growth through a 22-year LNG supply deal with Petrobras, supporting its position in the energy sector.
The outlook is positive with a consensus price target of $307.44, representing 7.2% upside potential. Risks include earnings volatility and capital expenditure demands from growth projects. Analyst sentiment is overwhelmingly bullish with 92.59% buy ratings, but investors should monitor execution on expansion initiatives and energy market dynamics.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cheniere Energy
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
